

Altus Pharmaceuticals Inc.
Form S-8
March 11, 2008

Table of Contents

As filed with the Securities and Exchange Commission on March 11, 2008

REGISTRATION NO. 333 -

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
under the
SECURITIES ACT OF 1933
ALTUS PHARMACEUTICALS INC.
(Exact Name of Registrant as Specified in Its Charter)**

Delaware
(State or Other Jurisdiction
of Incorporation or Organization)

04-3573277
(I.R.S. Employer
Identification No.)

**640 Memorial Drive
Cambridge, MA 02139**
(Address, Including Zip Code, of Principal Executive Offices)

Altus Pharmaceuticals Inc. Amended and Restated 2002 Employee, Director and Consultant Stock Plan, as amended
(Full Title of the Plan)

David D. Pendergast, Ph.D.
Executive Chairman
Altus Pharmaceuticals Inc.
640 Memorial Drive
Cambridge, MA 02139
(617) 299-2900

(Name, Address and Telephone Number, Including Area Code, of Agent For Service)
with copies to:

Jonathan L. Kravetz, Esq.
Megan N. Gates, Esq.
Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.
One Financial Center
Boston, Massachusetts 02111

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting
company

(Do not check if a smaller reporting company)

CALCULATION OF REGISTRATION FEE

Proposed
maximum

Proposed
maximum

Edgar Filing: Altus Pharmaceuticals Inc. - Form S-8

Title of securities to be registered	Amount to be registered ⁽¹⁾	offering price per share ⁽²⁾	aggregate offering price ⁽²⁾	Amount of registration fee
Common Stock, \$0.01 par value	1,144,157	\$ 5.61	\$6,418,721	\$ 252.26

(1) The number of shares of Common Stock stated above consists of 1,144,157 additional shares which may be sold upon the exercise of options and the issuance of stock awards which may hereafter be granted under the Altus Pharmaceuticals Inc. Amended and Restated 2002 Employee, Director and Consultant Stock Plan, as amended (the Plan). The maximum number of shares which may be sold upon the exercise of options or issuance of stock awards granted under the Plan is subject to adjustment in accordance with certain anti-dilution and other provisions of the Plan. Accordingly, pursuant to Rule 416 under the Securities

Act of 1933, as amended (the Securities Act), this Registration Statement covers, in addition to the number of shares stated above, an indeterminate number of shares which may be subject to grant or otherwise issuable upon the operation of any such anti-dilution and other provisions.

- (2) This calculation is made solely for the purpose of determining the registration fee pursuant to the provisions of Rule 457(c) and (h) under the Securities Act. The fee is calculated on the basis of the average of the high and low sale prices per share of the Common Stock on The Nasdaq Global Market as of a date (March 6, 2008) within five business days prior to filing this Registration Statement.

TABLE OF CONTENTS

PART I INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

Item 1. Plan Information.

Item 2. Registrant Information and Employee Plan Annual Information.

PART II INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

Item 3. Incorporation of Documents by Reference.

Item 4. Description of Securities.

Item 5. Interests of Named Experts and Counsel.

Item 6. Indemnification of Directors and Officers.

Item 7. Exemption from Registration Claimed.

Item 8. Exhibits.

Item 9. Undertakings.

SIGNATURES

INDEX OF EXHIBITS

EX-5 Opinion of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.

EX-23.2 Consent of Deloitte & Touche LLP

Table of Contents

EXPLANATORY NOTE

The contents of the previously filed Registration Statements on Form S-8 (File No. 333-134421 and File No. 333-145243) of the Registrant are hereby incorporated by reference. The purpose of this Form S-8 Registration Statement is to reflect an increase of 1,144,157 shares of Common Stock authorized for issuance under the Altus Pharmaceuticals Inc. Amended and Restated 2002 Employee, Director and Consultant Stock Plan, as amended (the Plan).

PART I

INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

Item 1. Plan Information.

The information required by Item 1 is included in documents sent or given by the Registrant to participants in the Plan covered by this Registration Statement pursuant to Rule 428(b)(1) under the Securities Act.

Item 2. Registrant Information and Employee Plan Annual Information.

The written statement required by Item 2 is included in documents sent or given by the Registrant to participants in the Plan covered by this Registration Statement pursuant to Rule 428(b)(1) under the Securities Act.

PART II

INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

Item 3. Incorporation of Documents by Reference.

The following documents filed by the Registrant with the Commission are incorporated herein by reference:

- (1) The Registrant's Annual Report on Form 10-K for the fiscal year ended December 31, 2007 filed on March 11, 2008 (File No. 000-51711);
- (2) The Registrant's Current Report on Form 8-K filed on January 30, 2008 (File No. 000-51711);
- (3) The Registrant's Current Report on Form 8-K filed on February 7, 2008 (File No. 000-51711);
- (4) The Registrant's Current Report on Form 8-K filed on February 28, 2008 (File No. 000-51711);
- (5) The Registrant's Current Report on Form 8-K filed on March 11, 2008 (File No. 000-51711); and
- (6) The description of the Registrant's Common Stock contained in the Registrant's Registration Statement on Form 8-A, filed with the Commission on January 11, 2006 (File No. 000-51711), including any amendment or report filed for the purpose of updating such description.

All reports and other documents filed by the Registrant after the date hereof pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act of 1934, prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be part hereof from the date of filing of such reports and documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for the purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

Item 4. Description of Securities.

Not applicable.

Table of Contents

Item 5. Interests of Named Experts and Counsel.

The validity of the issuance of the shares of Common Stock registered under this Registration Statement has been passed upon for the Registrant by Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. and members of that firm, their families and trusts for their benefit own an aggregate of approximately 12,794 shares of Common Stock of the Registrant and options and warrants to purchase 1,000 shares of Common Stock of the Registrant.

Item 6. Indemnification of Directors and Officers.

Incorporated herein by reference from Part II, Item 15 Indemnification of Directors and Officers of the Registrant's Registration Statement on Form S-3 (File No. 333-141414).

Item 7. Exemption from Registration Claimed.

Not applicable.

Item 8. Exhibits.

- (4.1) Restated Certificate of Incorporation of the Registrant. Filed as Exhibit 3.1 to the Registrant's Annual Report on Form 10-K for the fiscal year ended December 31, 2006, as amended (File No. 000-51711) and incorporated herein by reference.
- (4.2) Restated By-laws of the Registrant. Filed as Exhibit 3.4 to the Registrant's Registration Statement on Form S-1, as amended (File No. 333-129037) and incorporated herein by reference.
- (4.3) Form of Common Stock Certificate. Filed as Exhibit 4.1 to the Registrant's Registration Statement on Form S-1, as amended (File No. 333-129037) and incorporated herein by reference.
- (4.4) Amended and Restated Investor Rights Agreement, dated as of May 21, 2004. Filed as Exhibit 4.3 to the Registrant's Registration Statement on Form S-1, as amended (File No. 333-129037) and incorporated herein by reference.
- (4.5) Form of Common Stock Warrant to Adage Capital Partners, L.P. Filed as Exhibit 4.5 to the Registrant's Registration Statement on Form S-3 (File No. 333-141414) and incorporated herein by reference.
- (4.6) Form of Common Stock Warrant to Cystic Fibrosis Foundation Therapeutics, Inc. Filed as Exhibit 4.9 to the Registrant's Registration Statement on Form S-1, as amended (File No. 333-129037) and incorporated herein by reference.
- (4.7) Form of Common Stock Warrant to Cowen and Company, LLC. Filed as Exhibit 4.11 to the Registrant's Registration Statement on Form S-1, as amended (File No. 333-129037) and incorporated herein by reference.
- (4.8) Form of Series B Preferred Stock Warrant, as amended, together with a schedule of warrant holders. Filed as Exhibit 4.12 to the Registrant's Registration Statement on Form S-1, as amended (File No. 333-129037) and incorporated herein by reference.
- (4.9) Form of Series C Preferred Stock Warrant, together with a schedule of warrant holders. Filed as Exhibit 4.13 to the Registrant's Registration Statement on Form S-1, as amended (File No. 333-129037) and incorporated herein by reference.
- (5) Opinion of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. as to the legality of shares being registered. Filed herewith.
- (23.1) Consent of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. (included in opinion of counsel filed as Exhibit 5).

- (23.2) Consent of Deloitte & Touche LLP. Filed herewith.
 - (24) Power of Attorney to file future amendments (set forth on the signature page of this Registration Statement).
 - (99.1) Altus Pharmaceuticals Inc. Amended and Restated 2002 Employee, Director and Consultant Stock Plan, as amended. Filed as
-

Table of Contents

Exhibit 10.4 to the Registrant's Annual Report on Form 10-K for the fiscal year ended December 31, 2006, as amended (File No. 000-51711) and incorporated herein by reference.

Item 9. Undertakings.

(a) The undersigned Registrant hereby undertakes:

(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

(i) To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933;

(ii) To reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the Calculation of Registration Fee table in the effective Registration Statement.

(iii) To include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement;

Provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 that are incorporated by reference in this Registration Statement.

(2) That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

(b) The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act of 1933, each filing of the Registrant's annual report pursuant to Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934 that is incorporated by reference in this Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

(c) Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.

Table of Contents**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Cambridge, Massachusetts on March 11, 2008.

ALTUS PHARMACEUTICALS INC.

By: /s/ David D. Pendergast, Ph.D.
David D. Pendergast, Ph.D.
Executive Chairman

POWER OF ATTORNEY

Each person whose signature appears below constitutes and appoints David D. Pendergast, Jonathan I. Lieber and Bruce A. Leicher, and each of them singly, his true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution in each of them singly, for him and in his name, place and stead, and in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8 of Altus Pharmaceuticals Inc., and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting to the attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite or necessary to be done in or about the premises, as full to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that the attorneys-in-fact and agents or any of each of them or their substitute may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

Signature	Title	Date
/s/ David D. Pendergast, Ph.D.		March 11, 2008
David D. Pendergast, Ph.D.	Executive Chairman and Chairman of the Board (principal executive officer)	
/s/ Jonathan I. Lieber		March 11, 2008
Jonathan I. Lieber	Vice President, Chief Financial Officer and Treasurer (principal financial and accounting officer)	
/s/ Stewart Hen		March 11, 2008
Stewart Hen	Director	
/s/ Jonathan S. Leff		March 11, 2008
Jonathan S. Leff	Director	
/s/ Manuel A. Navia, Ph.D.		March 11, 2008
Manuel A. Navia, Ph.D.	Director	
/s/ Harry H. Penner, Jr.		March 11, 2008
	Director	

Harry H. Penner, Jr.

/s/ John P. Richard

March 11, 2008

John P. Richard

Director

/s/ Jonathan D. Root, M.D.

March 11, 2008

Jonathan D. Root, M.D.

Director

/s/ Michael S. Wyzga

March 11, 2008

Michael S. Wyzga

Director

Table of Contents

INDEX OF EXHIBITS

Exhibit Number	Description
(4.1)	Restated Certificate of Incorporation of the Registrant. Filed as Exhibit 3.1 to the Registrant's Annual Report on Form 10-K for the fiscal year ended December 31, 2006, as amended (File No. 000-51711) and incorporated herein by reference.
(4.2)	Restated By-laws of the Registrant. Filed as Exhibit 3.4 to the Registrant's Registration Statement on Form S-1, as amended (File No. 333-129037) and incorporated herein by reference.
(4.3)	Form of Common Stock Certificate. Filed as Exhibit 4.1 to the Registrant's Registration Statement on Form S-1, as amended (File No. 333-129037) and incorporated herein by reference.
(4.4)	Amended and Restated Investor Rights Agreement, dated as of May 21, 2004. Filed as Exhibit 4.3 to the Registrant's Registration Statement on Form S-1, as amended (File No. 333-129037) and incorporated herein by reference.
(4.5)	Form of Common Stock Warrant to Adage Capital Partners, L.P. Filed as Exhibit 4.5 to the Registrant's Registration Statement on Form S-3 (File No. 333-141414) and incorporated herein by reference.
(4.6)	Form of Common Stock Warrant to Cystic Fibrosis Foundation Therapeutics, Inc. Filed as Exhibit 4.9 to the Registrant's Registration Statement on Form S-1, as amended (File No. 333-129037) and incorporated herein by reference.
(4.7)	Form of Common Stock Warrant to Cowen and Company, LLC. Filed as Exhibit 4.11 to the Registrant's Registration Statement on Form S-1, as amended (File No. 333-129037) and incorporated herein by reference.
(4.8)	Form of Series B Preferred Stock Warrant, as amended, together with a schedule of warrant holders. Filed as Exhibit 4.12 to the Registrant's Registration Statement on Form S-1, as amended (File No. 333-129037) and incorporated herein by reference.
(4.9)	Form of Series C Preferred Stock Warrant, together with a schedule of warrant holders. Filed as Exhibit 4.13 to the Registrant's Registration Statement on Form S-1, as amended (File No. 333-129037) and incorporated herein by reference.
(5)	Opinion of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. as to the legality of shares being registered. Filed herewith.
(23.1)	Consent of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. (included in opinion of counsel filed as Exhibit 5).
(23.2)	Consent of Deloitte & Touche LLP. Filed herewith.
(24)	Power of Attorney to file future amendments (set forth on the signature page of this Registration Statement).

Edgar Filing: Altus Pharmaceuticals Inc. - Form S-8

- (99.1) Altus Pharmaceuticals Inc. Amended and Restated 2002 Employee, Director and Consultant Stock Plan, as amended. Filed as Exhibit 10.4 to the Registrant's Annual Report on Form 10-K for the fiscal year ended December 31, 2006, as amended (File No. 000-51711) and incorporated herein by reference.